JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report

Baricitinib, a JAK1/2 inhibitor, has shown promise in treating refractory oral lichen planus, as evidenced by a case report where a patient experienced significant improvement within one month of daily treatment. This case supports the expanding role of baricitinib, already FDA-approved for alopecia areata, in managing various inflammatory dermatologic conditions, including lichen planus.